Captured directly from Meta and the linked page on October 20, 2026. Live offers may change.

A creator in glasses introduces the product while holding a drink. The creator’s opening promise continues into an editorial introduction, repeated purchase options, customer stories, and FAQs. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
Melissa opens by waving what looks like an injection pen at the camera, so the objection is on screen before she says it. Her script then moves through the questions a GLP-1-curious viewer actually has: she says it isn't a medication, that it's built around three clinically studied branded ingredients, and that it's stimulant free ('because I know somebody's thinking this'). That last line is a smart move, since it answers the doubt in the viewer's head in her own voice. The link headline, 'No Prescriptions. No Needles. No Synthetics.', repeats the same three exclusions.
The video spends nearly all its time on what WLP-1 isn't and very little on what someone would notice after taking it, so the outcome stays abstract. The close leans on her claim that it's selling out fast, and nothing in the ad shows that. If you make one like this, keep the pen-prop opener and the objection handling, then add one specific moment of use (what changed at dinner, the afternoon snack she skipped), and swap the scarcity line for a concrete reason like the landing page's refund promise.
Showing the thing people fear in the first frame stops anyone who's been put off by injections.
Agreeing with the trend and then naming her objection makes her sound like the viewer, not a salesperson.
Answering the 'is this just another trendy bottle?' and 'is it full of caffeine?' questions before anyone asks builds trust.
The close hands the viewer a label for themselves and a next step.
No price or discount. The value is framed as avoiding needles and prescriptions, with 'Try Oral GLP-1 Support Now' and a 'Shop now' CTA.
The ad goes to the needle-free GLP-1 advertorial, a focused landing page. The blueprint opens with 'Skip the shot,' which matches Melissa's opener almost word for word, then lays out five reasons people choose the injection-free route (no needles or prescription, absorption, three pathways, side effects, the two-capsule routine), customer reports, the product block, FAQs and a refund promise. Everything she raises in the video has a section waiting for it, which is about as close a message match as you'll see. Ten ads in the Fluid library point to this page.
An advertorial for WLP-1 that frames the product as a needle-free route, with a co-founder byline, three benefit tiles, an early plan box, five numbered reasons, customer reports, FAQs and a refund guarantee. 10 Absorption Company ads in the Fluid library link here, mainly editorial-style statics and creator videos about no needles and no prescription.
States the GLP-1 claim, the no-needle framing and the price-from line with a study disclaimer, answering what this is and why read on.
Opens in the co-founders' voice with the brand's case against injections, answering who is talking and what problem they see.
Names fullness, quieter cravings and burning more at rest, answering what the product is claimed to do.
Offers 3-month, 6-month and monthly plans with badges and the guarantee, answering how to buy right away.
Numbered sections on cost, absorption, three pathways, side effects and the routine, answering the main objections one at a time.
Shares what customers report, answering whether people like the reader have tried it.
Restates WLP-1 with its plans, answering how to order after reading.
Covers remaining questions, answering the last doubts before purchase.
Promises a refund if it doesn't work, with free shipping and cancel-anytime tiles, answering what happens if it doesn't suit you.
Read the full breakdown of this page
One of 188 The Absorption Company ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 20, 2026. We record that an ad ran publicly, not how it performed.